Skip to content

Clinical effect and safety evaluation of PRP Injection in PVB in patients with PHN

Clinical effect and safety evaluation of PRP Injection in PVB in patients with PHN

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076478
Enrollment
Unknown
Registered
2023-10-10
Start date
2023-10-10
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PHN

Interventions

Group PRP :PRP injection in PVB
Group Comparison:Neutropin injection in PVB

Sponsors

Shanghai East Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age =18 years, =80 years, gender is not limited; (2) Meet the 2016 Chinese Expert Consensus Diagnostic Criteria for Postherpetic Neuralgia Diagnosis and Treatment, and the lesion segment is located in T1-T12. (3) Patients voluntarily signed an informed consent form and were able to cooperate in completing the treatment and questionnaires.

Exclusion criteria

Exclusion criteria: (1) Patients with contraindications to the use of PRP; (2) Combination of tumour, haematological system, severe cardiac, pulmonary, hepatic and renal insufficiency, coagulation dysfunction, etc; (3) Acute systemic infection; (4) Patients with open wounds at the laser irradiation site, skin damage or local infection at the puncture site; (5) Patients who are allergic to the drugs used in this study or other patients who are not suitable for nerve block; (6) Patients who are not suitable for this study for other reasons.

Design outcomes

Primary

MeasureTime frame
Pain;

Secondary

MeasureTime frame
Emotion;Sleep;Life quality;

Countries

China

Contacts

Public ContactXiangrui Wang

Shanghai East Hospital

xiangrui68@163.com+86 137 0190 1953

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026